Keywords: Pfizer, Xiapex, Dupuytren's contracture, Germany, IQWiG, AMNOG

Germany’s IQWiG finds no added benefit for Pfizer’s Xiapex

Article | 14 February 2012

Print This

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in